$ATOS So I was recently attracted to ATOS mostly due to the high IV on selling covered calls, and the potential of their Endoxifen drug and Covid nasal spray advancing through clinical trial, hopefully successfully ending in FDA approval, and having ~135 million in cash to support operations in the near term. Curious if any long term holders know the history of the two previous reverse stock splits. Were there any previous drug candidates that failed, or is Endoxifen their main/only drug candidate that they have had from the start of the company (Covid nasal spray can't have been started in 2013ish). I see a lot of potential in the company, but the two reverse stock splits is a bit worrying to me as an investor/speculator, hoping there is not a third!
1 Like